Joint Venture & Orthopaedic Research UK

Arash joined Orthopaedic Research UK in 2008 and became Chief Executive in 2016. Since then, he has been instrumental in shaping the organisation’s strategy and driving its growth, with a focus on strengthening governance and expanding its research, education, and innovation programmes.

An agile and collaborative leader, Arash is passionate about forging strategic partnerships across the musculoskeletal community to accelerate innovation and create meaningful impact in society. He holds a PhD in Medical Engineering and an MBA in Management, and serves as a trustee of the British Orthopaedic Research Society (BORS) as well as a member of the research committee at the Bone and Joint Infection Society (BAJIS).

A biomaterials scientist with a PhD from the University of Oxford, where she focused on the design and manufacture of bilayered scaffolds for osteochondral tissue regeneration. She has several years of postdoctoral and research visitor experience working with leading research groups at the University of Brighton and University College London (UCL). Her postdoctoral projects have focused on the development of an in vitro models of intervertebral disc degeneration,  the synthesis and characterization of hydrogels for cartilage tissue engineering,  development of a novel microfluidic-based method for the encapsulation of mesenchymal stem cells in alginate and investigation of plant-derived exosome-like nanovesicles as a potential therapeutic strategy for early-stage osteoarthritis. Her research has led to multiple peer-reviewed journal publications, as well as a book chapter in the Handbook of Extracellular Matrix published by Springer Nature.

Khatereh is a distinguished professional with a rich background in the biotech and pharmaceutical industries. She holds a PhD in biochemistry from King’s College London and an MBA from Henley Management College. Khatereh has over 18 years of experience in biotech/pharma, and most recently led MSD’s Search and Evaluation Business Development team in Europe and the Middle East, focusing on oncology. She co-founded and led reViral Ltd, securing $21M in funding. At Piramed Ltd, she played a key role in a major deal with Genentech and its acquisition by Roche. Her expertise and leadership have made her a key figure in the industry, contributing significantly to the development of innovative therapies and the advancement of oncology research.

Khatereh joined the Investment Sub-Committee in December 2025

Omar is a Life Sciences Innovation Specialist with a focus on commercialising healthcare enterprises and bridging the gap between industry and healthcare providers to facilitate the adoption of new technologies and best practices.

With a background in business development, sales, and marketing, Omar possesses deep knowledge of the medical innovation and healthcare sectors. He excels in problem identification, definition, and segmentation.

Omar is dedicated to studying consumer behavior and has hands-on experience in evaluating and crafting value propositions for products targeting multiple stakeholders. His key strengths lie in empathy, effective communication, and a customer-centric approach to achieving success.

He holds a Master of Business Administration (MBA) in Business Administration and Management from Imperial College Business School, and a BA (Hons) in Business from the University of the West of England.

Omar has held various roles in prestigious organizations, including Faculty at the National Association of Primary Care (NAPC), Strategic Development Lead for Health Innovation at Imperial College London, Mentor Healthcare at King’s Entrepreneurship Institute, and Lecturer at both Imperial College Business School and the Frankfurt School of Finance & Management.

Additionally, he co-founded Vita Health Care Solutions, serves as a mentor at MedTech SuperConnector (MSK Innovation Accelerator Programme, supported by ORUK), and held positions such as Innovation Account Lead, Innovation Advisor at Imperial College Health Partners, Product Specialist at KARL STORZ Endoscopy (UK) Ltd, and Managed Service Salesman at BSG.

Omar joined the Investment Sub-Committee in February 2026.

Jenny is a Non-Executive Director with Medway NHS Foundation Trust. She sits on boards and committees for The Design Museum, Imperial College London’s Venture Mentoring Service, the Egypt Exploration Society; and on the global advisory board for Business of Data. She is a mentor on Imperial College’s Imperial Venture Mentoring Scheme and the Engineering Faculty’s Imperial Technology Experts Service; and an advisor to various start-ups in the FinTech, MedTech and social impact space.

Originally from Singapore, after graduating from the London School of Economics, Jenny embarked on a 20-year career in Investment Banking. Starting in Equities, she has worked across client relationship management, infrastructure, software engineering, program management, big data and AI. Her most recent role was as Credit Suisse’s Global Head of Electronic Communications Surveillance, running a global regulatory compliance platform that detects potential malicious behaviour; leveraging natural language processing and deep learning to cognitively learn human context; identify patterns to create behavioural models; and detect anomalous signals.

Jenny actively promotes education in STEM, gender equality, diversity and inclusion. She is also a recipient of the Tech Star award at the “Women in Banking and Finance Annual Awards for Achievement”.

Khaled joined the Finance, Investment, and Audit Committee in December 2025. He is a Trauma, Orthopaedic, and Sports Surgeon at Imperial College Healthcare NHS Trust, Fortius Clinic, and The Cromwell Hospital, bringing over a decade of experience in delivering world-class care. His clinical expertise spans trauma, sports injuries, and joint reconstruction, and he has treated professional and elite athletes across multiple disciplines – including football – helping them return to peak performance.